Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 5/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12726682 | 1.00 | KDM4E (0.53) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL1638546 | 1.00 | KDM4E (0.53) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL1638791 | 0.78 | MAPT (0.78) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL1638795 | 0.78 | MAPT (0.78) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL1638330 | 0.78 | GAA (0.51) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL1638328 | 0.78 | GAA (0.51) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL1637236 | 0.77 | MAPT (0.54) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL1637237 | 0.77 | MAPT (0.54) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL1638683 | 0.77 | MAPT (0.49) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL1639486 | 0.77 | MAPT (0.49) | KDM4ENPC1RAB9ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098309-A1 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS | ACUMEN PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2194975-A2 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS | Acumen Pharmaceuticals, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009009768-A2 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS | ACUMEN PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098309-A1 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS | APP, APBA1, BACE1 | KDM4E 4638/4885NPC1 732/4885RAB9A 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.